Todd Louis Rosenblat, MD
Overview
Dr. Rosenblat is an assistant professor of medicine at Columbia University Medical Center, College of Physicians and Surgeons. He is a hematologist/oncologist with expertise in the diagnosis and treatment of acute and chronic leukemias, myeloproliferative neoplasms, and myelodysplastic syndrome.
His research focuses on development of new and more effective treatments for patients with acute myeloid leukemia. This includes the development of novel drugs and drug combinations, as well as immunotherapy for myeloid leukemias. He received his MD degree from Stony Brook University and completed his fellowship in medical oncology/hematology at Memorial Sloan-Kettering Cancer Center.
Areas of Expertise / Conditions Treated
- Acute Leukemia
- Acute Lymphocytic Leukemia
- Acute Myelogenous Leukemia
- Aplastic Anemia
- Chronic Leukemia
- Chronic Lymphoid Leukemia
- Chronic Myelogenous Leukemia
- Essential Thrombocythemia
- Hairy Cell Leukemia
- Hematologic Malignancy
- Large Granular Lymphocytic Leukemia
- Leukemia
- Lymphoblastic Leukemia
- Myelodysplastic Syndrome
- Myelofibrosis
- Myeloproliferative Disease
- Polycythemia Vera
- Waldenstrom's Macroglobulinemia
Academic Appointments
- Assistant Professor of Medicine at CUMC
Hospital Affiliations
- NewYork-Presbyterian / Columbia University Irving Medical Center
Gender
- Male
Schedule an Appointment
Phone Appointments
Connect Patient Portal
For existing patients, login to make an appointment, view documentation or contact your care provider.
Location(s)
Insurance Accepted
Aetna
- Aetna Signature Administrators
- Medicare Managed Care
- NYP Employee Plan
- NY Signature
- PPO
- Student Health
Affinity Health Plan
- Medicaid Managed Care
AgeWell
- Medicare Managed Care
- Special Needs
Amerigroup of New Jersey
- New Jersey Services (Medicaid Managed Care)
Amida Care
- Special Needs
Cigna
- EPO
- Great West (National)
- HMO
- Medicare Managed Care
- POS
- PPO
Emblem/GHI
- Medicare Managed Care
- PPO
Emblem/HIP
- ConnectiCare
- EPO
- Essential Plan
- HMO
- Medicare Managed Care
- POS
- PPO
- Select Care (Exchange)
- Vytra
Empire Blue Cross Blue Shield HealthPlus
- Child/Family Health Plus
- Essential Plan
Fidelis Care
- Child/Family Health Plus
- Essential Plan
- Medicaid Managed Care
- Medicare Managed Care
Healthfirst
- Child/Family Health Plus
- Leaf (Exchange)
- Medicare Managed Care
Local 1199
- Local 1199
MagnaCare (National)
- MagnaCare
Medicare
- Railroad
- Traditional Medicare
Multiplan
- Multiplan
MVP Health Care
- Child/Family Health Plus
- Essential Plan
- HMO
- Medicaid Managed Care
Quality Health Management
- Quality Health Management
RiverSpring
- Special Needs
UnitedHealthcare
- Compass (Exchange)
- Empire Plan
- HMO
- Medicaid (Community Plan)
- Oxford Freedom
- Oxford HMO
- Oxford Liberty
- POS
- PPO
VNSNY CHOICE
- SelectHealth
WellCare
- Medicaid Managed Care
- Medicare Managed Care
World Trade Center Health Plan
- World Trade Center Health Plan
Credentials & Experience
Education & Training
- MD, State University of New York at Stony Brook, School of Medicine
- 2003 Stonybrook School of Medicine
- Residency: NYU Medical Center
- Fellowship: Memorial Sloan-Kettering Cancer Center
Committees, Societies, Councils
American Society of Clinical Oncology
American Society of Hematology
Southwest Oncology Group, Leukemia Committee
Board Certifications
- Medical Oncology
- Hematology
- Internal Medicine
Research
Selected Publications
Renier J. Brentjens, Marco L. Davila, Isabelle Riviere, Jae Park, Xiuyan Wang, Lindsay G. Cowell, Shirley Bartido, Jolanta Stefanski, Clare Taylor, Malgorzata Olszewska, Oriana Borquez-Ojeda, Jinrong Qu, Teresa Wasielewska, Qing He, Yvette Bernal, Ivelise V. Rijo, Cyrus Hedvat, Rachel Kobos, Kevin Curran, Peter Steinherz, Joseph Jurcic, Todd Rosenblat, Peter Maslak, Mark Frattini and Michel Sadelain. CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia. Sci Transl Med 2013: 177(5);177ra38
Altman JK, Rademaker A, Cull E, Weitner BB, Ofran Y, Rosenblat TL, Haidau A, Park JH, Ram SL, Orsini JM Jr, Sandhu S, Catchatourian R, Trifilio SM, Adel NG, Frankfurt O, Stein EM, Mallios G, Deblasio T, Jurcic JG, Nimer S, Peterson LC,Kwaan HC, Rowe JM, Douer D, Tallman MS. Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death. Leuk Res. 2013;37(9):1004-9
Roboz GJ, Rosenblat T, Arellano M, Gobbi M, Altman JK, Montesinos P, O'Connell C, Solomon SR, Pigneux A, Vey N, Hills R, Jacobsen TF, Gianella-Borradori A, Foss O, Vetrhusand S, Giles FJ. International Randomized Phase III Study of Elacytarabine Versus Investigator Choice in Patients With Relapsed/Refractory Acute Myeloid Leukemia. J Clin Oncol. 2014 May 19
For a complete list of publications, please visit PubMed.gov